November 17, 2021
A throng of new medicines will join the reimbursement price list in Japan on November 25, including Pfizer’s JAK inhibitor Cibinqo (abrocitinib), Eli Lilly’s RET kinase inhibitor Retevmo (selpercatinib), and Astellas Pharma’s Padcev (enfortumab vedotin), an antibody-drug conjugate (ADC). The...read more